Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

The Integrated Genomic Landscape of Thymic Epithelial Tumors

(2018) Milan Radovich et al.   CANCER CELL

Early B cell changes predict autoimmunity following combination immune checkpoint blockade

(2018) Rituparna Das et al.   JOURNAL OF CLINICAL INVESTIGATION

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial

(2018) Jinhyun Cho et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study

(2018) Giuseppe Giaccone et al.   LANCET ONCOLOGY

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1

(2018) Andrew L Mammen et al.   ANNALS OF THE RHEUMATIC DISEASES

Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial

(2017) Christopher R Heery et al.   LANCET ONCOLOGY

Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial

(2017) James L Gulley et al.   LANCET ONCOLOGY

Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

(2017) Renee N. Donahue et al.   Journal for ImmunoTherapy of Cancer

Clinicopathologic and Prognostic Implications of Programmed Death Ligand 1 Expression in Thymoma

(2016) Shintaro Yokoyama et al.   ANNALS OF THORACIC SURGERY

Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire

(2016) David Y. Oh et al.   CANCER RESEARCH

Mutanome directed cancer immunotherapy

(2016) Mathias Vormehr et al.   CURRENT OPINION IN IMMUNOLOGY

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

(2016) Lisa Zimmer et al.   EUROPEAN JOURNAL OF CANCER

Immune-related adverse events with immune checkpoint blockade: a comprehensive review

(2016) J.M. Michot et al.   EUROPEAN JOURNAL OF CANCER

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

(2016) Howard L Kaufman et al.   LANCET ONCOLOGY

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?

(2015) Daniel Sanghoon Shin et al.   CURRENT OPINION IN IMMUNOLOGY

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

(2015) Sukhmani K. Padda et al.   Journal of Thoracic Oncology

Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial

(2015) Anish Thomas et al.   LANCET ONCOLOGY

Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma

(2015) Yuki Katsuya et al.   LUNG CANCER

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells

(2015) B. Boyerinas et al.   Cancer Immunology Research

Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

(2014) Ester Simeone et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Mutations of epigenetic regulatory genes are common in thymic carcinomas

(2014) Yisong Wang et al.   Scientific Reports

Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue

(2013) M. J. Gerdes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Chemotherapy and targeted agents for thymic malignancies

(2012) Nicolas Girard   Expert Review of Anticancer Therapy

Thymic epithelial cells: working class heroes for T cell development and repertoire selection

(2012) Graham Anderson et al.   TRENDS IN IMMUNOLOGY

Thymoma and autoimmunity

(2011) Shahar Shelly et al.   Cellular & Molecular Immunology

Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy

(2011) Benedetto Farsaci et al.   INTERNATIONAL JOURNAL OF CANCER

The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells

(2011) S. Amarnath et al.   Science Translational Medicine

The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies

(2009) J. Ozao-Choy et al.   CANCER RESEARCH

Thymoma and thymic carcinoma

(2009) Federico Venuta et al.   EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH